1. Introduction {#s0005}
===============

Over 12 million individuals worldwide have tested positive for Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) coronavirus 19 (COVID-19) up to date ([@b0005]). The pandemic has triggered massive quantities of scientific publications reporting data on COVID-19 of clinical- and scientific-relevance. The typical presentation of SARS-CoV-2 involves fever and respiratory symptoms. However, the recognition of neuroinvolvement of COVID-19 is increasing daily since the initial indications in February 2020 ([@b0010]). Currently, PubMed database search alone for the keywords "covid"/"sars-cov-2"/"coronavirus" and "neurologic"/"CNS" results in over 120,000 matches. Cohort studies and case reports describe various brain manifestations suggestive of COVID-19 etiology. At the time of "flattening the epidemic curve", this growing body of research characterizing acute/subacute phase of infection calls for a synthesis.

The aim of this systematic review is to provide a synthesis of early evidence of brain abnormalities in patients with COVID-19 in acute/subacute phase, with the focus on (1) frequency of particular brain abnormality types, and (2) topographical distribution of registered brain abnormalities.

2. Methods {#s0010}
==========

2.1. Search strategy and study selection {#s0015}
----------------------------------------

A systematic search of literature was performed in line with the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement ([@b0015], [@b0020]) ([Fig. 1](#f0005){ref-type="fig"} ). Search was implemented for PubMed, GoogleScholar, and ScienceDirect databases. The search strategy and keywords was as follows: ((covid\[Title/Abstract\]) OR (sars-cov-2\[Title/Abstract\]) OR (coronavirus\[Title/Abstract\])) AND (brain\[Title/Abstract\])*.* Search was limited to articles published between January 01 and July 05, 2020. The review protocol was not previously registered. Initial search was screened for duplicates. Then, two independent authors (ARE and SC) identified potential articles through (1) screening titles and abstracts, and (2) screening full text using inclusion and exclusion criteria (below). Search was finalized on July 06, 2020.Fig. 1PRISMA (2009) flow diagram of the study.

2.2. Inclusion and exclusion criteria {#s0020}
-------------------------------------

Original contributions, which presented data on brain structural and/or functional abnormalities (or absence of such) suggestive of COVID-19 etiology, were included in the current systematic review. Articles were excluded in case of no original neuroimaging data, no full text, no available English version of the article, or in case of reviews, letters to editor, correspondence, perspective, and opinion not containing original data of interest.

2.3. Data extraction {#s0025}
--------------------

Data was extracted by two independent authors (ARE and SC) with the use of standardized form where rows contained information about the authors and year of publication, while columns indicated the following: study type (i.e., case report or cohort study), number of patients who completed at least one brain scanning session, age, sex, survival status, pre-existing medical conditions, RNA PCR fluid (CSF) status for SARS-CoV-2, early symptoms of COVID-19 (i.e., before hospital admission), symptoms of COVID-19 at/after hospital admission, symptoms of COVID-19 the day of brain scan (separately for 1st brain imaging and follow-ups), brain imaging interpretation, procedures performed on the brain during that hospital visit/stay, brain imaging modality, brain imaging results (separately for each scanning session in case of follow-ups).

3. Results {#s0030}
==========

3.1. Study selection and characteristics {#s0035}
----------------------------------------

Initial search resulted in a collection of 295 records. Duplicates were removed, leaving 286 original contributions. Screening titles and abstracts excluded unrelated articles (n = 127); review articles (n = 62); perspective articles (n = 14); articles with English version not available (n = 1). The remaining 82 potential articles were entered into full text screening using inclusion and exclusion criteria. This step excluded articles with no original data on the brain structure or function with suggested relevance to COVID-19 (n = 42); no full text available (n = 10). Out of the identified 30 eligible articles, one article was excluded from the synthesis as patient SARS-CoV-2+ status was not confirmed neither in the swab specimen nor real-time polymerase chain reaction in the cerebrospinal fluid ([@b0085]). Additional three article were excluded as the relationship between brain abnormalities and COVID-19 infection was noted by the authors as improbable. In detail, the authors attributed reported brain abnormalities rather to other/pre-existing medical conditions, previous pathological situations or interpreted them as potentially coincidental with COVID-19 ([@b0025], [@b0055], [@b0135]). Therefore, we entered a total of 26 articles (including 21 case reports, and 5 cohort studies) into the final synthesis. All 361 participants from 26 studies were patients with confirmed COVID-19 infection (with swab and/or CSF test) ([@b0180]). Brain abnormalities suggestive of COVID-19 etiology were present in 124/361 (34%) reported cases. Available demographic and illness characteristics are shown in [Table 1](#t0005){ref-type="table"} .Table 1Characteristics of the included studies.![](fx1a_lrg.gif)![](fx1b_lrg.gif)![](fx1c_lrg.gif)![](fx1d_lrg.gif)[^1][^2][^3]

3.2. Typology of brain abnormalities in COVID-19 {#s0040}
------------------------------------------------

The most frequent brain abnormalities were brain WM hyperintensities on MRI and hypodensities on CT, which together accounted for 76% of affected cases ([Table 2](#t0010){ref-type="table"} ). Hyperintensities in cerebral WM were reported in 66/124 (53% affected cases). Those abnormalities were noted in bilateral medial temporal lobes \[Z\] ([@b0160]), frontal, occipital, parietal \[C ([@b0040]): 4/21 cases\], all of the above plus temporal lobes \[D ([@b0045]); P ([@b0105]): 12/27; W ([@b0145]): 10/11 cases; Q ([@b0110]): 16/37\]. Changes were also registered in insular cortex \[P ([@b0105]): 3/27\], subinsular regions \[Z\] ([@b0160]), cingulate gyri \[P ([@b0105]): 3/27\], cerebral peduncle and internal capsule \[β\] ([@b0170]), thalamus \[Z ([@b0160]); D ([@b0045]); H ([@b0070]), midbrain \[Z\] ([@b0160]), pons \[D ([@b0045]); β ([@b0170]), parahippocampal gyri and basal ganglia \[H\] ([@b0070]), splenium of corpus callosum \[L ([@b0090]); β ([@b0170]), olfactory nerves/bulb \[R ([@b0115]), W ([@b0135]) and gyrus rectus \[W\] ([@b0135]), or described as diffuse \[α ([@b0165]), W ([@b0145]): 10/11 cases; Q ([@b0110]): 11/37; U ([@b0130]). Three patients showed lateralized hyperintensities: one case of right prefrontal involvement \[K\] ([@b0080]), one case of right temporal lobe, inferior horn of lateral ventricle and hippocampus \[S\] ([@b0120]), and one case of left WM, cortical and deep gray matter and midbrain \[A\] ([@b0030]). Diffuse leukoencephalopathy was further reported in 4/124 (3%) in bilateral cerebellar hemispheres and middle cerebellar peduncles \[W ([@b0145]): 4/11\].Table 2Brain imaging features in patients with COVID-19 in acute/subacute phase.![](fx2a_lrg.gif)![](fx2b_lrg.gif)![](fx2c_lrg.gif)![](fx2d_lrg.gif)![](fx2e_lrg.gif)![](fx2f_lrg.gif)![](fx2g_lrg.gif)![](fx2h_lrg.gif)[^4][^5][^6][^7][^8][^9][^10][^11][^12][^13][^14][^15][^16][^17][^18][^19][^20][^21][^22]

Hypodensities were noted in additional 29/124 (23% affected cases), and were primarily registered as diffuse changes in bilateral WM \[E ([@b0050]); X ([@b0150]): 26/242 cases\]. Two case studies described hypodensities in amygdala \[F\] ([@b0060]), supratentorial leptomeningeal \[N\] ([@b0095]), left occipital lobe \[F\] ([@b0060]) in WM and gray matter).

Other brain abnormalities were reported as follows. *Microhemorrhages* in WM were noted in 16/124 (13%) with bilateral diffuse presentation \[W ([@b0145]): 5/11\], in corpus callosum \[W ([@b0145]): 4/7; Y ([@b0155]), and putamen \[F\] ([@b0060]), bilateral juxtacortical WM and internal capsule \[Y\] ([@b0155]); or diffuse \[Q ([@b0110]): 9/37\]. *Infarct* was reported in 13/124 (10%) and involved bilateral anterior \[X ([@b0150]): 9/242\] and posterior \[X ([@b0150]): 4/242\] circulation territories. *Hemorrhages* were noted in 7/124 (6%) and included: bilateral posterior parieto-occipital area (J) ([@b0075]) and amygdala \[F\] ([@b0060]); as well as left frontal \[T\] ([@b0125]) and occipital areas \[E\] ([@b0050]); right temporal area \[E\] ([@b0050]); temporal plus frontal lobes and Sylvian fissure \[B\] ([@b0035]); and right posterior parieto-occipital area \[I\] ([@b0075]); brain stem and pons \[F\] ([@b0060]); and corpus callosum \[I\] ([@b0075]); and intraventricular layering in the occipital horns of lateral ventricles \[U\] ([@b0130]). *Swelling/edema, restricted diffusion* was reported in 4/124 (3%) in bilateral WM with diffuse presentation \[F\] ([@b0060]), in posterior parieto-occipital regions \[I ([@b0075]), J ([@b0075]), thalamic nuclei \[F\] ([@b0060]), subinsular regions \[F\] ([@b0060]), basal ganglia \[J\] ([@b0075]), cingulate gyri \[F\] ([@b0060]), cerebellar hemispheres \[J\] ([@b0075]), right frontal lobe \[J\] ([@b0075]), and right temporal lobe \[O\] ([@b0100]), as well as brain stem, pons and splenium \[F\] ([@b0060]). *Seizures* were noted in 4/124 (3%) in bilateral fronto-temporal regions \[N ([@b0095]); α ([@b0165])\], right frontal \[K\] ([@b0080]) and right centropatieral area \[M\] ([@b0095]). EEG demonstrated *wave slowing* in 4/124 (3%) patient cases \[G ([@b0065]), H ([@b0070]), U ([@b0130]) Z ([@b0160]). CT-angio revealed *increased enhancement* in 1/124 (1%) patient case bilateral supratentorial leptomeningeal \[B\] ([@b0035]). *Ischemia* was characterized in another patient case (1/124 (1%) in left frontal lobe \[T\] ([@b0125]). *Hematoma* was also identified in one case report (1/124 (1%) and located in right subdural and frontal area \[B\] ([@b0035]). *Smaller olfactory bulb* was noted in one case report 1/124 (1%). One report on spontaneous brain activity revealed no abnormalities in the Default Mode Network \[H\] ([@b0070]).

3.3. Topography of brain abnormalities in COVID-19 {#s0045}
--------------------------------------------------

Diffuse subcortical and deep WM abnormalities were the most prominent. A cumulative of 62/124 (50%) of cases presented brain abnormality in either anterior areas \[D ([@b0045]); N ([@b0095]); α ([@b0165]), X ([@b0150]): 9/242 cases, Z ([@b0160]) or posterior regions \[I ([@b0075]), J ([@b0075]), X ([@b0150]): 4/242 cases\] or anterior-posterior regions \[C ([@b0040]): 4/21 cases; E ([@b0050]); P ([@b0105]): 4/27 cases; W ([@b0145]): 10/11 cases; Q ([@b0110]): 20/37\]. Of those, several patients additionally presented brain abnormalities which were lateralized \[I ([@b0075]); E ([@b0050]); J ([@b0075]), cerebellar (W ([@b0145]): 4/11 cases\], located in cortex \[C ([@b0040]): 4/21 cases\], deep brain structures \[D ([@b0045]); P ([@b0105]): 3/27 cases\], scattered in juxtacortical WM \[Y\] ([@b0155]), or diffuse \[α\] ([@b0165]). Unspecified brain location for brain waves slowing on EEG recording was reported in four cases \[G ([@b0065]); H ([@b0070]); U ([@b0130]); Z ([@b0160]).

Anterior brain regions were affected bilaterally in 45/124, i.e., 36% of patients with brain abnormalities. Those primarily involved juxta/subcortical and deep white matter (WM) hyperintensities in medial temporal lobe \[Z\] ([@b0160]), frontal and temporal lobes \[W ([@b0145]): 10/11 cases\], frontal lobe \[P ([@b0105]): 4/27 cases, including 1/27 also in temporal lobe\], or temporal lobe (D ([@b0045]), Q ([@b0110]): 16/37; R ([@b0115]), or gyrus rectus and olfactory bulb (V) ([@b0140]). Seizures were noted with the EEG in fronto-temporal regions for two patients \[N ([@b0095]); α ([@b0165])\]. One study reported infarcts in anterior circulation territories \[X ([@b0150]): 9/242 cases\].

Posterior brain regions presented bilateral abnormalities in 22/124 (18% of patients with brain abnormalities). One patient showed subcortical WM hypodensities reaching from occipito-parieto-temporal reaching toward posterior frontal tracts \[E\] ([@b0050]). Subcortical and deep WM hyperintensities were diffuse \[U\] ([@b0130]), included occipital and parietal regions \[P ([@b0105]): 4/27 and 3/27 cases respectively\], or were accompanied by mild restricted diffusion in subcortical and deep WM in occipital lobe \[W ([@b0145]): 10/11 cases, including 7 cases with additional abnormalities in juxtacortical WM\]. Two other cases showed focal vasogenic/cytotoxic edema \[I ([@b0075]), J ([@b0075])\] in posterior parieto-occipital regions, while one was further accompanied by restricted diffusion and hemorrhages \[J\] ([@b0075]). Another study reported infarcts in posterior circulation territories \[X ([@b0150]): 4/242 cases\].

Exclusively right cerebral hemisphere abnormalities were noted in 8/124 (6%) affected cases and were not specific to any one particular location or type of abnormality. Hyperintensities were noted in temporal mesial lobe, inferior horn of lateral ventricle and hippocampus in one patient \[S\] ([@b0120])). One case report showed restricted diffusion with associated edema in frontal lobe \[J\] ([@b0075]). Another patient showed subdural and frontal intracerebral hematoma, accompanied by subarachnoid hemorrhage in frontal, temporal regions and Sylvian fissure \[B\] ([@b0035]). Intraventrivular hemorrhage was noted in one case \[U\] ([@b0130]). Focal seizures in centroparietal regions were noted in another two case reports \[M ([@b0095]); K ([@b0080])\]. One case report revealed hemorrhage in posterior parieto-occipital region \[I\] ([@b0075]). Another case reported severe brain swelling in the right temporal lobe, which was previously injured by hemorrhagic infarction \[O\] ([@b0100]).

Exclusively left cerebral hemisphere abnormalities were reported in 3/124 (2%) affected cases. Those included diffuse hyperintensities in WM, cortical and deep gray matter \[A\] ([@b0030]), hypodensity in occipital cortex and WM \[F\] ([@b0060]), and aneurysmal hemorrhage with delayed cerebral ischemia in frontal lobe \[T\] ([@b0125]).

Cerebellar abnormalities were evident in 7/124 (6%) affected cases, and involved white matter hypodensity \[N\] ([@b0095]) or diffuse leukoencephalopathy \[W ([@b0145]): 4/11 cases\], restricted diffusion with associated edema \[J\] ([@b0075]), and increased enhancement on CT-angio \[B\] ([@b0035]).

Deep brain structures were affected in 9/124 (7%) affected cases, out of which 4 comprised insula and cingulate gyri abnormalities \[P ([@b0105]): 3/27 cases\], and swelling and restricted diffusion with peripheral enhancement \[F\] ([@b0060]). The same patient \[F\] ([@b0060]) also showed swelling and restricted diffusion with peripheral enhancement in thalamus and putamen, as well as hypodensity/hemorrhage in amygdala \[F\] ([@b0060]). Four cases showed internal capsul hyperintensities \[β\] ([@b0170]) or microbleeds \[Y\] ([@b0155]), hyperintensities in thalamic nuclei \[D ([@b0045]); Z ([@b0160])\] and subinsula \[Z\] ([@b0160]), or cerebral peduncle \[β\] ([@b0170]). Additionally, restricted diffusion with edema was noted in basal ganglia (no details available) in one patient \[J\] ([@b0075]).

The midline structures of the brain were affected in 12/124 (10%) affected cases and mainly included abnormalities in the corpus callosum, i.e., hyperintensities \[L ([@b0090]); β ([@b0170])\], hemorrhage \[I\] ([@b0075]), microhemorrhages \[W ([@b0145])\]: 4/7 cases; Y ([@b0155]), and swelling and restricted diffusion \[F\] ([@b0060]). Additionally, one of those patients \[F\] ([@b0060]) showed signs of swelling and hemorrhage in brain stem and hemorrhage in pons. Hyperintensities were noted in midbrain \[A ([@b0030]); Z ([@b0160])\] and pons \[D ([@b0045]); β ([@b0170])\].

Only 6/361 patients were scanned with CTP, CT-/MR-angio. In 4 of those 6 cases, the results were not showing arteriovenous malformation or aneurysms or acute vascular occlusion, or were unremarkable. Two patients showed frontal subarachnoid hemorrhage or ischemia, one of them only on the follow-up scan.

In the majority of reviewed cases 237/361 (66%), CT/MRI did not reveal any acute/subacute brain abnormalities that were attributed to COVID-19 as the most probable cause. Those included 17/21 patients \[C\] ([@b0040]), 15/27 \[P\] ([@b0105]), and 205/242 \[X\] ([@b0150]). Additionally, one study did not report neuroimaging results for 16/27 patients as they did not show white matter T2 hyperintensities and/or microhemorrhages W ([@b0145]). However, such description does not allow to uniformly determine whether brain scans in those 16 patients were unremarkable.

Finally, three case reports showed brain abnormalities (in the form of cortical hyperintensities) on the initial scan, but a complete resolution of lesions at 1-month follow-up scan \[C ([@b0040]); K ([@b0080])\]; V ([@b0140]). Additionally, one case showed EEG signal abnormalities that were no longer present at around two weeks after Sars-CoV-2 detection \[Y\] ([@b0155]).

4. Discussion {#s0050}
=============

This systematic review provides a synthesis of early evidence on brain abnormalities suggestive of COVID-19 etiology in patients in acute/subacute phase. Collectively, published reports show that out of patients with available brain imaging, 66% patients do not present brain manifestations of presumed COVID-19 etiology. Various brain abnormalities were present in the remaining 34% reviewed cases. Together, this suggests that early neurologic symptoms, which were the reason for referral for brain imaging, may appear earlier than the brain structural changes can be detected with the available technology. Future studies should consider employing myelin imaging or WM tractography based on diffusion-weighted imaging data to provide additional description of more intricate brain WM changes in COVID-19. Alternatively, transient neurologic symptoms may also be related to acute/subacute brain alterations at the level of functional networks. This hypothesis can be examined for example with the use of resting state functional MRI sequences. This methodology may be especially useful considering the respiratory complications in COVID-19.

The primary neuroimaging feature involved WM hyperintensities on or MRI hypodensities on CT, which was observed in 76% of the affected cases. These changes were primarily diffuse in the cerebral WM, however, the provided examples of brain scans for cohort studies \[W ([@b0145]), X ([@b0150])\] also reveal the increased density of WM changes in close proximity to the ventricles. As the brain images were not provided for all reported cases, we cannot verify whether the increased periventricular presentation is a common characteristics. At the same time, the involvement of cerebellar, midline- or deep brain structures was reported infrequently. Together, the exhibited topographical pattern of the WM abnormalities allows us to speculate about attributing these changes to leukoencephalopathy, leukoaraiosis (LA) or rarefield WM not restricted to periventricular area. This interpretation is in line with the notion made by the Authors of the original articles \[F ([@b0060]), W ([@b0145])\]. LA is one of the most prominent characteristics of the aging brain, often asymptomatic and only revealed with neuroimaging. However, the analyzed data further suggest that the prevalence of LA is higher in this patient population than expected for age. Other possible interpretations may include encephalitis as suggested in several reports ([@b0040], [@b0045], [@b0065], [@b0090], [@b0110]), acute necrotizing encephalitis ([@b0160]), encephalomyelitis ([@b0030], [@b0170]), demyelination ([@b0165], [@b0130], [@b0170]), or microangiopathy ([@b0070]). Therefore, we encourage future studies to report more detailed description of the WM changes in order to establish differential characteristics of COVID-19-related vs. age-related changes in WM. One way to address this as well as to enable future meta-analyses, is to report the scores on the Fazekas scale ([@b0175]).

The potential neuropathological associations of LA may include hypoxia, hypoperfusion, as well as demyelination or axonal loss, with consequent disconnection syndromes. However, the potential pathogeneses of brain abnormalities in COVID-19 patients remain unclear and are beyond the scope of this systematic review. We restricted the analyses to the synthesis of available evidence regarding types and topography of registered brain abnormalities. Future longitudinal studies are needed to address the mechanisms of brain manifestations, neurologic sequelae in COVID-19, and the directional relationship between neuroinvasive actions of SARS-CoV-2 and respiratory failure.

Other types of brain abnormalities were less frequently observed and included aneurysm, hematoma, hemorrhage and seizure. These brain abnormalities were reported infrequently as compared to LA cases. Thus, it can be hypothesized, that if the presentation of these conditions is related to COVID-19, than perhaps it may be enhanced or accelerated with systemic inflammation rather than directly triggered by the infection. The neuropathological associations of these brain abnormalities should be examined in the future studies.

Importantly, in three patient cases with cortical hyperintensities, there was a resolution of lesions noted on a 30-day follow-up. Comparisons with other reports are limited as only two more research teams presented an extensive follow-up brain scan in one patient \[F ([@b0060]); U ([@b0130])\]. Also, one of the patients with EEG showed resolution of signal abnormalities at around 2-week mark following Sars-CoV-2+ detection \[Y\] ([@b0155]). The hypothesis on transient character of brain abnormalities should be assessed in future research.

This systematic review has limitations. It is based on the available evidence with the assumption that the original contributions report all evident brain abnormalities and their proposed interpretation of the relationship with COVID-19 is accurate. Neuroimaging findings were excluded from the current review and analysis in cases where the authors reported them to be unrelated to the COVID-19, coincidental, or where the authors provided a different explanation for the findings. For example, one study reported 134/242 patients to show WM hypodensities/hyperintensities, out of which in 108 changes were "as much as expected for age" ([@b0150]). Importantly, as the relationship between brain structure/function and COVID-19 infection is not clear yet, such interpretations may lead to underreporting brain issues in this patient population and the current results should be treated with caution. Furthermore, our literature search only included articles with title and/or abstract containing the word "brain" and at least one of the following "covid"/"sars-cov-2"/"coronavirus". As this holds a potential of missing original contributions of interest, we checked the results of the following extended search strategies: ((covid\[Title/Abstract\]) OR (sars-cov-2\[Title/Abstract\]) OR (coronavirus\[Title/Abstract\])) AND (brain\[Title/Abstract\]) OR (CNS\[Title/Abstract\]), which yielded 106,581 results; and ((covid\[Title/Abstract\]) OR (sars-cov-2\[Title/Abstract\]) OR (coronavirus\[Title/Abstract\])) AND (brain\[Title/Abstract\]) OR (neurologic\[Title/Abstract\]), which yielded 83,533 results as of July 06, 2020. However, for the purpose of a timely contribution on early evidence of abnormalities due to COVID-19 only in the brain and not other parts of the CNS, we analyzed the data from the initial, more narrow and precise search. Our future research plans involve a more holistic literature search employing the above extended the search strategies. Another limitation is posed by the reasons for referral to CT/MRI/EEG imaging in the analyzed studies as well as bias related to the case reports, such as the selection of patient cases for presentation. Missing data on neurologic symptoms in original articles did not allow us to analyze the relationships with the revealed brain abnormalities patterns. Due to few published cohort studies, we incorporated case reports into a cumulative synthesis, but we were unable to employ meta-analytic approach. Future systematic reviews should include meta-analysis of larger cohort studies once they become available.

5. Conclusion {#s0055}
=============

We found that brain images in acute/subacute patients with COVID-19 are predominantly characterized by diffuse cerebral WM hyperintensities/hypodensities. The available evidence allows to speculate about the higher prevalence of leukoencephalopathy, leukoaraiosis or rarefield WM in this patient population than expected for age. Large cohort studies reporting details of registered brain abnormalities are needed in order to establish (1) the incidence of brain abnormalities, (2) neurologic sequelae, and (3) pathophysiological associations of neuroinvasion in COVID-19.

Appendix A. Supplementary data {#s0065}
==============================

The following are the Supplementary data to this article:Supplementary data 1

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.bbi.2020.07.014>.

[^1]: *Notes*. N/A -- non-applicable, M -- male, F -- female, GCS -- Glasgow Coma Score, CT -- Computed Tomography, MRI -- Magnetic Resonance Imaging, CNS --Cerebrospinal Fluid, CSF -- Chemical-physical cerebrospinal fluid, PCR-- Polymerase chain reaction, RNA- Ribonucleic acid, RT-PCR -- Real-time polymerase chain reaction.

[^2]: \* Authors provided neuroimaging results for 11/27 cases. The inclusion of those 11 cases was based onnoted abnormalities interms of white matter T2 hyperintensities (more than expected for age-related microangiopathy based on visual qualitative assessment) and/or microhemorrhages (defined as ≤ 4 mm in size). Microhemorrhages confined to any areas of acute/subacute infarcts were excluded.

[^3]: \*\* 242 out of 3661 patients were MRI scanned. The authors reportthe most common clinical indications for brain imaging in their cohort to be: altered mental status (n = 102), syncope/fall (n = 79), or focal neurologic deficit (n = 30).

[^4]: *Notes*. "x" indicates the presence of abnormality on brain scan, CT -- Computed Tomography; MRI -- Magnetic Resonance Imaging, EEG -- Electroencephalography, N/A -- non-applicable, \* acute, surrounded by edema and caused midline shift

[^5]: \*\* became chronic

[^6]: \*\*\* re-reabsorbing with persistent perilesional brain edema and midline shift

[^7]: †with associated mass effect and cortical sulcal effacement

[^8]: †† three focal seizures lasting approximately 30 s each

[^9]: ††† focal status epilepticus

[^10]: ‡consistent with mild microvascular disease but without acute intracranial lesion

[^11]: ‡‡ no evidence of brain edema

[^12]: ‡‡‡ no signs of cerebral vasospasm

[^13]: \*\*microhemorrhages varied between 5 and 6 to innumerable. Predominantly punctate, smaller than 3-mm in size. no concomitant larger intracranial hemorrhage. One patient with microhemorrhages has a prior brain MRI available (7 days before current hospital admission), which revealed that all hemorrhages were new. 4 in 7 patients had CT 3--7 days before MRI - no punctate microhemorrhages shown.

[^14]: \*\*No patients with altered mental status as the indication for brain imaging demonstrated acute or subacute infarct or acute intracranial hemorrhage

[^15]: \*\*\*the authors did not clearly state if hyperintensities comprised all cases of abnormalities.

[^16]: ¥ White matter microangiopathy was more than expected for age in 26 patients and in additional 108 patients as much as expected for age.

[^17]: ¥¥ posterior frontal and temporo-parieto-occipital symmetric bilateral hypodensity of the subcortical white matter.

[^18]: ¥¥¥ Default Mode Network was studied based on four nodes: the medial prefrontal cortex, the posterior cingulate cortex, and bilateral inferior parietal lobules

[^19]: \$ extensive and isolated WM microhemorrhages

[^20]: \$\$ the signal alteration in the cortex completely disappeared

[^21]: \$\$\$ the olfactory bulbs were thinner and slightly less hyperintense

[^22]: δ improved brain swelling
